Dr. Kerstin M. Bode-Greuel, Managing Partner, Bioscience Valuation LLC
Kerstin M. Bode-Greuel, MD, Ph.D., is founding and managing partner of Bioscience Valuation with offices in Germany and the USA and of Bioscience Market Research based in the USA. Kerstin has over 18 years’ experience in pharmaceutical R&D and strategic marketing, covering virtually all therapy areas. She has worked for Bayer AG in a number of senior positions including R&D and global project management. At Bayer, Kerstin was member of the task force responsible for the implementation of value-driven portfolio management. Prior to founding Bioscience Valuation, Kerstin worked as an independent management consultant for five years.
Kerstin advises pharmaceutical and biotech companies on issues related to valuation and risk and portfolio management. She is widely known as an expert in financial project and portfolio evaluation, R&D and commercial risk minimization, and in real options analysis. Kerstin developed and enhanced modern, quantitative project and portfolio management methods that are based on thorough financial analyses. Those financial analyses provide a direct measure of value creation. In addition, Kerstin assists her clients in implementing an efficient portfolio management process. Kerstin publishes in peer-reviewed journals and has authored two expert reports for SCRIP (‘Financial Project Evaluation and Risk Analysis in Pharmaceutical Development’ and ‘Real Options Evaluation in Pharmaceutical R&D’). She is Associate Lecturer at the University of Essen for the subject of financial valuation and portfolio management. Her workshops and presentations dealing with advanced portfolio management techniques are very well received at international conferences.
Kerstin studied medicine in Marburg (Germany), Nottingham (UK) and Cambridge (UK) and was educated in corporate finance at the Wharton School of the University of Pennsylvania (USA). She is a member of the Decision Sciences Institute of Atlanta (USA).